MedTrace Logo

Pharmacokinetic Studies Participation Survey

NCT00923468 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2017-07-02

No results posted yet for this study

Summary

Background:

* A pharmacokinetic (PK) study of a new drug involves taking several blood samples over a period of time from study participants to determine how the body handles the substance. These studies provide critical information about new drugs.
* Often, patients or parents of children in drug studies choose not to participate in optional PK studies that are part of the study protocol.
* A better understanding of why patients or families do or do not agree to participate in PK studies may help researchers make it easier for people to participate in them.

Objectives:

* To learn why some people do or do not agree to participate in PK blood sampling studies.

Eligibility:

* Patients 18 years of age and older and parents or guardians of children who are participating in a study of a drug that includes the option of participating in PK sampling.

Design:

* Participants fill out a 2-page survey asking about why they did or did not participate in the study's PK sampling.

Conditions

  • Relapsed Solid Tumors
  • Relapsed Leukemia
  • Relapsed Brain Tumors

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-23
Primary Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00923468 on ClinicalTrials.gov